华领医药上半年卖出300多万盒药 拟持续探索血糖管理市场空间

证券日报
Aug 21

截至目前,多格列艾汀(商品名:华堂宁)是华领医药核心产品。资料显示,该药物为全球首个葡萄糖激酶(GK)激活剂类创新药,可通过改善胰岛β细胞功能及胰岛素抵抗,帮助恢复血糖稳态调节能力。该药于2022年在中国获批上市,用于治疗成人2型糖尿病。  8月20日晚间,华领医药发布了2026年半年报。数据显示,该公司上半年实现收入3.79亿元,同比增长74%;销售多格列艾汀约305.5万盒,同比增长73%。 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10